Juha O Rinne

List of Publications by Year
in descending order

138 papers	8,081 citations	71102 41 h-index
148 all docs	148 docs citations	148 times ranked

51608   86 g-index
11275 citing authors

#	ARTICLE	IF	CITATIONS
1	Education as a moderator of middle-age cardiovascular risk factor—old-age cognition relationships: testing cognitive reserve hypothesis in epidemiological study. Age and Ageing, 2022, 51, .	1.6	8
2	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [<scp>¹¹C</scp>]<scp>PBR28</scp> and Machine Learning Analysis. Movement Disorders, 2022, 37, 119-129.	3.9	18
3	Differences in brain changes between adults with childhood-onset epilepsy and controls: A prospective population-based study. Acta Neurologica Scandinavica, 2022, 145, 322-331.	2.1	2
4	Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation. EJNMMI Research, 2022, 12, 6.	2.5	7
5	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease – Study Protocol and Baseline Characteristics. Frontiers in Neurology, 2022, 13, 826423.	2.4	7
6	Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer's disease: a potential early sign of AD. Alzheimer's Research and Therapy, 2022, 14, 37.	6.2	12
7	Atlas of type 2 dopamine receptors in the human brain: Age and sex dependent variability in a large PET cohort. NeuroImage, 2022, 255, 119149.	4.2	8
8	Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy. Movement Disorders, 2022, 37, 1776-1778.	3.9	0
9	Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [<scp>¹⁸F</scp>]<scp>FMPEP</scp>–<i>d</i>₂. Movement Disorders, 2022, 37, 1673-1682.	3.9	4
10	Association of Early β-Amyloid Accumulation and Neuroinflammation Measured With [¹¹C]PBR28 in Elderly Individuals Without Dementia. Neurology, 2021, 96, e1608-e1619.	1.1	30
11	27-Hydroxycholesterol, cognition, and brain imaging markers in the FINGER randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 56.	6.2	18
12	Brain Glucose Metabolism in Health, Obesity, and Cognitive Decline—Does Insulin Have Anything to Do with It? A Narrative Review. Journal of Clinical Medicine, 2021, 10, 1532.	2.4	32
13	Change in CAIDE Dementia Risk Score and Neuroimaging Biomarkers During a 2-Year Multidomain Lifestyle Randomized Controlled Trial: Results of a Post-Hoc Subgroup Analysis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1407-1414.	3.6	17
14	Effects of White Matter Hyperintensities on Verbal Fluency in Healthy Older Adults and MCI/AD. Frontiers in Aging Neuroscience, 2021, 13, 614809.	3.4	3
15	Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2021, 86, 40-44.	2.2	4
16	Increased risk for dementia in neurofibromatosis type 1. Genetics in Medicine, 2021, 23, 2219-2222.	2.4	8
17	Cerebral grey matter density is associated with neuroreceptor and neurotransporter availability: A combined PET and MRI study. NeuroImage, 2021, 235, 117968.	4.2	9
18	Oral Glucose Tolerance Test Predicts Episodic Memory Decline: A 10-Year Population-Based Follow-up Study. Diabetes Care, 2021, 44, dc210042.	8.6	2

#	Article	IF	Citations
19	(S)-[18F]THK5117 brain uptake is associated with AÎ² plaques and MAO-B enzyme in a mouse model of Alzheimer's disease. Neuropharmacology, 2021, 196, 108676.	4.1	7
20	Episodic memory and cortical amyloid pathology: PET study in cognitively discordant twin pairs. Neurobiology of Aging, 2021, 108, 122-132.	3.1	1
21	Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study. Theranostics, 2021, 11, 6644-6667.	10.0	42
22	Chronic lowâ€grade inflammation predicts greater decline in verbal fluency and wordâ€list learning on 10 years' followâ€up. Alzheimer's and Dementia, 2021, 17, .	0.8	0
23	Brain amyloid load and cognitive trajectories in older individuals at risk for dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
24	Domain-specific cognitive effects of white matter pathology in old age, mild cognitive impairment and Alzheimerâ€™s disease. Aging, Neuropsychology, and Cognition, 2020, 27, 453-470.	1.3	11
25	Comparison of high and low molar activity TSPO tracer [18F]F-DPA in a mouse model of Alzheimerâ€™s disease. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1012-1020.	4.3	16
26	Training working memory updating in Parkinsonâ€™s disease: A randomised controlled trial. Neuropsychological Rehabilitation, 2020, 30, 673-708.	1.6	28
27	Disentangling the Role of Working Memory in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 572037.	3.4	6
28	White Matter Changes on Diffusion Tensor Imaging in the FINGER Randomized Controlled Trial. Journal of Alzheimer's Disease, 2020, 78, 75-86.	2.6	17
29	Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 606.	2.4	21
30	Change in CAIDE dementia risk score and neuroimaging biomarkers during a 2â€year multidomain lifestyle randomized controlled trial. Alzheimer's and Dementia, 2020, 16, e040879.	0.8	0
31	Effect of APOEâ€Ê4 gene dose on regional early neuroinflammation and betaâ€amyloid deposition in cognitively normal elderly volunteers. Alzheimer's and Dementia, 2020, 16, e043359.	0.8	1
32	Brain betaâ€amyloid in twin pairs discordant for episodic memory performance. Alzheimer's and Dementia, 2020, 16, e045741.	0.8	0
33	Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	26
34	Interindividual variability and lateralization of Î¼-opioid receptors in the human brain. NeuroImage, 2020, 217, 116922.	4.2	60
35	Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety. Neuropsychopharmacology, 2020, 45, 1953-1959.	5.4	44
36	Magia: Robust Automated Image Processing and Kinetic Modeling Toolbox for PET Neuroinformatics. Frontiers in Neuroinformatics, 2020, 14, 3.	2.5	41

#	Article	IF	Citations
37	Motives for physical activity in older men and women: A twin study using accelerometer–measured physical activity. Scandinavian Journal of Medicine and Science in Sports, 2020, 30, 1409-1422.	2.9	8
38	Application of the PET ligand [11C]ORM-13070 to examine receptor occupancy by the α2C-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain. EJNMMI Research, 2020, 10, 152.	2.5	4
39	Insulin-Independent and Dependent Glucose Transporters in Brain Mural Cells in CADASIL. Frontiers in Genetics, 2020, 11, 1022.	2.3	4
40	The Older Finnish Twin Cohort — 45 Years of Follow-up. Twin Research and Human Genetics, 2019, 22, 240-254.	0.6	68
41	Cessation of anti-VLA-4 therapy in a focal rat model of multiple sclerosis causes an increase in neuroinflammation. EJNMMI Research, 2019, 9, 38.	2.5	4
42	Midlife Insulin Resistance as a Predictor for Late-Life Cognitive Function and Cerebrovascular Lesions. Journal of Alzheimer's Disease, 2019, 72, 215-228.	2.6	20
43	Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimer's Research and Therapy, 2019, 11, 53.	6.2	75
44	Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 459.	2.4	23
45	Effect of genotype and age on cerebral [18F]FDG uptake varies between transgenic APPSwe-PS1dE9 and Tg2576 mouse models of Alzheimer's disease. Scientific Reports, 2019, 9, 5700.	3.3	8
46	Natalizumab treatment reduces microglial activation in the white matter of the MS brain. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e574.	6.0	34
47	Brain β-Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline. American Journal of Neuroradiology, 2019, 40, 80-85.	2.4	10
48	Chronic diseases and objectively monitored physical activity profile among aged individuals – a cross-sectional twin cohort study. Annals of Medicine, 2019, 51, 78-87.	3.8	25
49	Cognitive Effects of White Matter Pathology in Normal and Pathological Aging. Journal of Alzheimer's Disease, 2019, 67, 489-493.	2.6	5
50	Midlife insulin resistance, *APOE* genotype, and late-life brain amyloid accumulation. Neurology, 2018, 90, e1150-e1157.	1.1	53
51	Microglial activation, white matter tract damage, and disability in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e443.	6.0	51
52	Albuminuria and Microalbuminuria as Predictors of Cognitive Performance in a General Population: An 11-Year Follow-Up Study. Journal of Alzheimer's Disease, 2018, 62, 635-648.	2.6	16
53	Brain amyloid load and its associations with cognition and vascular risk factors in FINGER Study. Neurology, 2018, 90, e206-e213.	1.1	36
54	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58

#	Article	IF	Citations
55	Longitudinal changes in the brain in mild cognitive impairment: a magnetic resonance imaging study using the visual rating method and tensor-based morphometry. Acta Radiologica, 2018, 59, 973-979.	1.1	3
56	Neuroinflammation Appears Early on PET Imaging and Then Plateaus in a Mouse Model of Alzheimer Disease. Journal of Nuclear Medicine, 2018, 59, 509-515.	5.0	40
57	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
58	P2â€605: EDUCATION, MIDDLEâ€AGE BODY MASS INDEX AND OLD AGE COGNITIVE FUNCTIONING: A POPULATIONâ€BASED QUASIâ€EXPERIMENTAL TWIN STUDY. Alzheimer's and Dementia, 2018, 14, P971.	0.8	0
59	O2â€03â€01: MIDLIFE INSULIN RESISTANCE AND LATEâ€LIFE COGNITION, BRAIN AMYLOID ACCUMULATION, AND CEREBROVASCULAR LESIONS. Alzheimer's and Dementia, 2018, 14, P613.	0.8	0
60	[18F]F-DPA for the detection of activated microglia in a mouse model of Alzheimer's disease. Nuclear Medicine and Biology, 2018, 67, 1-9.	0.6	27
61	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of AÎ² species. NeuroImage: Clinical, 2018, 20, 603-610.	2.7	11
62	Long-term leisure-time physical activity and other health habits as predictors of objectively monitored late-life physical activity â€" A 40-year twin study. Scientific Reports, 2018, 8, 9400.	3.3	18
63	Objectively measured physical activity profile and cognition in Finnish elderly twins. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 263-271.	3.7	14
64	[18F]FMPEP-d2 PET imaging shows age- and genotype-dependent impairments in the availability of cannabinoid receptor 1 in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2018, 69, 199-208.	3.1	23
65	Radiosynthesis and Preclinical Evaluation of [18F]F-DPA, A Novel Pyrazolo[1,5a]pyrimidine Acetamide TSPO Radioligand, in Healthy Sprague Dawley Rats. Molecular Imaging and Biology, 2017, 19, 736-745.	2.6	31
66	Cognitive Outcome in Childhood-Onset Epilepsy: A Five-Decade Prospective Cohort Study. Journal of the International Neuropsychological Society, 2017, 23, 332-340.	1.8	23
67	Cardiovascular Risk Factors From Childhood and MidlifeÂCognitiveÂPerformance. Journal of the American College of Cardiology, 2017, 69, 2279-2289.	2.8	100
68	Applicability of [11 C]PIB micro-PET imaging for inÂvivo follow-up of anti-amyloid treatment effects in APP23 mouse model. Neurobiology of Aging, 2017, 57, 84-94.	3.1	17
69	Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis. Journal of Nuclear Medicine, 2017, 58, 1646-1651.	5.0	63
70	Association Between Childhood-Onset Epilepsy and Amyloid Burden 5 Decades Later. JAMA Neurology, 2017, 74, 583.	9.0	52
71	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.8	113
72	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.8	108

#	Article	IF	Citations
73	Brain glucose metabolism and its relation to amyloid load in middle-aged adults with childhood-onset epilepsy. Epilepsy Research, 2017, 137, 69-72.	1.6	11
74	Brain regional iron contents in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2017, 45, 28-32.	2.2	16
75	Parkinsonian Patients with Striatal Cribriform State Present Rapidly Progressive Axial Parkinsonism. European Neurology, 2017, 78, 119-124.	1.4	0
76	Increased dopamine release after working-memory updating training: Neurochemical correlates of transfer. Scientific Reports, 2017, 7, 7160.	3.3	20
77	PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease. Stem Cell Reports, 2017, 9, 1885-1897.	4.8	239
78	Brain energy metabolism and neuroinflammation in ageing APP/PS1-21 mice using longitudinal ^{18}F-FDG and ^{18}F-DPA-714 PET imaging. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2870-2882.	4.3	53
79	SNCA mutation p.Ala53Glu is derived from a common founder in the Finnish population. Neurobiology of Aging, 2017, 50, 168.e5-168.e8.	3.1	7
80	Imaging of microglial activation in MS using PET: Research use and potential future clinical application. Multiple Sclerosis Journal, 2017, 23, 496-504.	3.0	24
81	[P3â€"574]: ASSOCIATIONS OF LEUCOCYTE TELOMERE LENGTH WITH BRAINÂMRIÂAND PIBâ€PET MEASURES: THEÂFINGER STUDY. Alzheimer's and Dementia, 2017, 13, P1199.	0.8	0
82	[P3â€"579]: IMPACT OF BASELINE BRAIN MRI MEASURES ON COGNITIVE EFFECTS OF A MULTIDOMAIN INTERVENTION: THE FINGER RANDOMIZED CONTROLLED TRIAL. Alzheimer's and Dementia, 2017, 13, P1202.	0.8	0
83	Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, andÂcognition. Journal of Alzheimer's Disease, 2017, 59, 695-705.	2.6	44
84	Regional gray matter correlates of memory for emotion-laden words in middle-aged and older adults: A voxel-based morphometry study. PLoS ONE, 2017, 12, e0182541.	2.5	2
85	[P3â€"170]: HUMAN IPSCâ€DERIVED ALZHEIMER's DISEASE ASTROCYTES RECAPITULATE DISEASEâ€RELATED PHENOTYPES. Alzheimer's and Dementia, 2017, 13, P999.	0.8	0
86	Midlife Physical Activity and Cognition Later in Life: A Prospective Twin Study. Journal of Alzheimer's Disease, 2016, 54, 1303-1317.	2.6	16
87	P2â€422: Insulin Resistance is Associated With a Decline in Verbal Fluency During 11 Years of Followâ€Up. Alzheimer's and Dementia, 2016, 12, P806.	0.8	0
88	P3-030: White Matter Changes on Diffusion Tensor Imaging in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). , 2016, 12, P828-P828.		0
89	P3-367: Cognitive Reserve as Indexed by Educational and Occupational Attainment Moderates the Association Between Cardiovascular Disease and Dementia. , 2016, 12, P989-P990.		0
90	18 F-labeling syntheses and preclinical evaluation of functionalized nanoliposomes for Alzheimer's disease. European Journal of Pharmaceutical Sciences, 2016, 88, 257-266.	4.0	6

#	ARTICLE	IF	CITATIONS
91	Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. American Journal of Human Genetics, 2016, 98, 735-743.	6.2	65
92	Pittsburgh compound B imaging and cerebrospinal fluid amyloid-Î² in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	7.6	107
93	Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese. Brain Research, 2016, 1652, 97-102.	2.2	2
94	Middle age selfâ€report risk score predicts cognitive functioning and dementia in 20â€"40Âyears. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 118-125.	2.4	17
95	Bapineuzumab for mild to moderate Alzheimerâ€™s disease in two global, randomized, phase 3 trials. Alzheimer's Research and Therapy, 2016, 8, 18.	6.2	208
96	Parametric Binding Images of the TSPO Ligand ^{18}F-DPA-714. Journal of Nuclear Medicine, 2016, 57, 1543-1547.	5.0	23
97	Biochemical and clinical effects of Whey protein supplementation in Parkinson's disease: A pilot study. Journal of the Neurological Sciences, 2016, 367, 162-170.	0.6	43
98	Visual rating method and tensor-based morphometry in the diagnosis of mild cognitive impairment and Alzheimer's disease: a comparative magnetic resonance imaging study. Acta Radiologica, 2016, 57, 348-355.	1.1	9
99	Use of amyloid-PET to determine cutpoints for CSF markers. Neurology, 2016, 86, 50-58.	1.1	54
100	Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 48, 123-133.	2.6	8
101	DT-02-06: Middle age protective score based onÂself-reported measures predictsÂdementia status in old age: A population-based study with 28-year follow-up. , 2015, 11, P335-P335.		0
102	A Phase II Trial of Tideglusib in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 75-88.	2.6	363
103	In Vivo PET Imaging Demonstrates Diminished Microglial Activation After Fingolimod Treatment in an Animal Model of Multiple Sclerosis. Journal of Nuclear Medicine, 2015, 56, 305-310.	5.0	57
104	Automated Reference Region Extraction and Population-Based Input Function for Brain [^{11}C]TMSX PET Image Analyses. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 157-165.	4.3	40
105	Quantification of [^{18}F]DPA-714 Binding in the Human Brain: Initial Studies in Healthy Controls and Alzheimer'S Disease Patients. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 766-772.	4.3	99
106	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
107	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
108	Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells. Journal of Neuroinflammation, 2015, 12, 81.	7.2	59

#	Article	IF	Citations
109	Imaging neuroinflammation in multiple sclerosis using TSPO-PET. Clinical and Translational Imaging, 2015, 3, 461-473.	2.1	41
110	Insulin resistance is associated with poorer verbal fluency performance in women. Diabetologia, 2015, 58, 2545-2553.	6.3	37
111	Long-Term Test–Retest Reliability of Striatal and Extrastriatal Dopamine D$_{2/3}$ Receptor Binding: Study with [^{11}C]Raclopride and High-Resolution PET. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1199-1205.	4.3	72
112	Hypermetabolism of Olivary Nuclei in a Patient with Progressive Ataxia and Palatal Tremor. Tremor and Other Hyperkinetic Movements, 2015, 5, 342.	2.0	3
113	Prospective Flutemetamol Positron Emission Tomography and Histopathology in Normal Pressure Hydrocephalus. Neurodegenerative Diseases, 2014, 13, 237-245.	1.4	18
114	Synthesis and evaluation of a 18F-curcumin derivate for Î²-amyloid plaque imaging. Bioorganic and Medicinal Chemistry, 2014, 22, 2753-2762.	3.0	32
115	In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ^{11}C-PK11195. Journal of Nuclear Medicine, 2014, 55, 939-944.	5.0	132
116	Mortality in Parkinson's disease is not associated with the severity of early dopaminergic defect. Parkinsonism and Related Disorders, 2014, 20, 894-897.	2.2	5
117	Cortical 11C-PIB Uptake is Associated with Age, APOE Genotype, and Gender in "Healthy Aging". Journal of Alzheimer's Disease, 2014, 41, 193-202.	2.6	33
118	P3-189: DIAGNOSTIC EFFECTIVENESS OF QUANTITATIVE [18F]FLUTEMETAMOL PET IMAGING IN SUBJECTS WITH NORMAL PRESSURE HYDROCEPHALUS USING BIOPSY HISTOPATHOLOGY STANDARD OF TRUTH FOR DETECTION OF FIBRILLAR AMYLOID B. , 2014, 10, P699-P699.		0
119	Reduced Striatal Dopamine Synthesis Capacity is Associated with Symptoms of Depression in Patients with de novo Unmedicated Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 325-329.	2.8	16
120	[18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid Î² detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathologica, 2012, 124, 833-845.	7.7	75
121	Effects of Working-Memory Training on Striatal Dopamine Release. Science, 2011, 333, 718-718.	12.6	191
122	11C-PiB PET assessment of change in fibrillar amyloid-Î² load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology, The, 2010, 9, 363-372.	10.2	674
123	C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse, 2009, 63, 907-912.	1.2	156
124	Positron Emission Tomography in the Differential Diagnosis of Parkinsonism. Journal of Movement Disorders, 2009, 2, 53-57.	1.3	4
125	Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. Parkinsonism and Related Disorders, 2008, 14, 553-557.	2.2	134
126	Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathologica, 2001, 102, 160-166.	7.7	116

#	Article	IF	Citations
127	[18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse, 2001, 40, 193-200.	1.2	54
128	Rate of progression in Parkinson's disease: A 6â€{¹⁸F]fluoroâ€Łâ€dopa PET study. Movement Disorders, 2001, 16, 608-615.	3.9	201
129	Sex Differences in Extrastriatal Dopamine D2-Like Receptors in the Human Brain. American Journal of Psychiatry, 2001, 158, 308-311.	7.2	138
130	Reproducibility and Effect of Levodopa on Dopamine Transporter Function Measurements: A [18F]CFT PET Study. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 1604-1609.	4.3	69
131	The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Medical Journal, 2000, 41, 167.	2.2	155
132	Drug development for neurodegenerative diseases: role of PET. Annals of Medicine, 1999, 31, 444-449.	3.8	3
133	The Glu318Gly mutation of the presenilin-1 gene does not necessarily cause Alzheimer's disease. Annals of Neurology, 1998, 44, 965-967.	5.3	53
134	Picture naming deficits in vascular dementia and Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 126-140.	1.3	46
135	Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: Differing response in relation to presynaptic dopaminergic dysfunction. , 1997, 27, 336-346.		24
136	PET examination of the monoamine transporter with [11c]β-CIT and [11c]β-CFT in early parkinson's disease. Synapse, 1995, 21, 97-103.	1.2	67
137	Decrease in Human Striatal Dopamine D_2 Receptor Density with Age: A PET Study with [^{11}C]Raclopride. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 310-314.	4.3	186
138	Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Annals of Neurology, 1989, 26, 47-50.	5.3	285